x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Proactive - Interviews for investors

Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.

business investing

All Episodes

00:01:53

Just the Facts: Sovereign Metals confirms Kasiya...

Proactive - Interviews for investors ·

2025/02/19

Sovereign Metals Ltd has confirmed that graphite concentrate from the Kasiya Rutile-Graphite Project in Malawi meets all key requirements for refractory applications. Testing was conducted by German laboratories ProGraphite and Dorfner Anzaplan. Refractories, which are used in high-temperature industrial processes, account for 24% of the natural graphite market, making them the second-largest end-use sector after battery applications, which hold a 52% market share. The refractories market

en

00:04:33

Medicus Pharma advances Phase 2 clinical study, eyes...

Proactive - Interviews for investors ·

2025/02/18

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce significant progress in the company’s Phase 2 clinical study, currently being conducted across nine clinical sites in the United States. The study has now randomized over 50% of its expected 60 patients. The company remains on track to complete an interim data analysis by Q1 2025 and plans to submit its findings to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. The purpose

en

00:07:55

BioHarvest Sciences surpasses 50 million dollars in...

Proactive - Interviews for investors ·

2025/02/18

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to announce a major achievement for the company—VINIA, its flagship red grape cell-based supplement, has now surpassed $50 million in cumulative sales. Notably, the vast majority of these sales have occurred within just four years since the product’s U.S. launch in May 2021, highlighting its rapid market adoption and consumer demand. VINIA®, developed using BioHarvest’s proprietary Botanical Synthesis platform technology, has

en

00:05:44

BitFuFu expands U.S. Bitcoin mining presence with...

Proactive - Interviews for investors ·

2025/02/18

BitFuFu Vice President of Investor Relations Charley Brady joined Steve Darling from Proactive to discuss the company’s North American expansion and its latest acquisition plans. BitFuFu has signed a letter of intent to acquire a majority stake in a 51-megawatt (MW) Bitcoin mining facility in Oklahoma. Strategically located in an unpopulated area, the fully constructed facility boasts a reliable power supply with an average electricity cost of just 3 cents per kilowatt-hour. The site operates

en

00:05:20

Nevis Brands expands national footprint with launch...

Proactive - Interviews for investors ·

2025/02/18

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce a major milestone for the company—the national launch of Happy Apple, a hemp-derived THC beverage designed to offer a smooth, relaxing experience without the drawbacks of alcohol. Already a popular choice in Washington State’s regulated dispensary market, Happy Apple will now be available in dozens of states across the U.S., marking a significant expansion for Nevis Brands. The company has successfully adapted its

en

00:03:46

Kairos Pharma secures funding from Department of...

Proactive - Interviews for investors ·

2025/02/18

Kairos Pharma CEO John Yu joined Steve Darling from Proactive to share major updates on the company’s latest cancer research developments. A significant milestone in its academic partnership with Cedars-Sinai Medical Center has been achieved, as Cedars-Sinai secured $600,000 in funding from the Department of Defense’s Lung Cancer Research Program. This grant will accelerate work on an innovative therapy designed to address chemotherapy resistance and cachexia—a severe condition causing muscle loss

en

00:06:47

KEFI Gold and Copper chair discusses significant...

Proactive - Interviews for investors ·

2025/02/18

KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) executive chairman Harry Anagnostaras-Adams talked with Proactive's Stephen Gunnion about the company’s latest resource update for the Hawiah project in Saudi Arabia. He highlighted that the total reported resource at Hawiah has now reached 3 million ounces of gold equivalent, with the potential to double based on new exploration licenses. He noted that this reinforces the project’s status as a key development asset in Saudi Arabia. Anagnostaras-Adams

en

00:16:34

ImmuPharma CEO on oversubscribed fundraising and...

Proactive - Interviews for investors ·

2025/02/18

ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio with more on the company’s recent £2.91 million oversubscribed equity fundraising. McCarthy emphasised that this year marks a major turning point for ImmuPharma, building on extensive work from the past two to three years. The fundraising was primarily backed by long-standing investors, including Lanstead, which contributed two-thirds of the total. McCarthy highlighted that the funding will accelerate

en

00:06:16

Gelion’s big battery leap: CEO John Wood on...

Proactive - Interviews for investors ·

2025/02/18

Gelion PLC (AIM:GELN) CEO John Wood talked with Proactive's Stephen Gunnion about the company’s latest advancements in battery technology. Wood discussed Gelion’s progress, including the release of GEN 3 results achieving 400 Wh/kg, commercial agreements with Glencore and Ionblox Inc., and a £1 million contract with Group Energy Pty Ltd. A key focus was Gelion’s development of sulfur cathodes, which are lighter, safer, and more cost-effective than traditional battery materials. Wood highlighted the

en

00:09:34

Learning Technologies Group CEO Jonathan Satchell on...

Proactive - Interviews for investors ·

2025/02/18

Learning Technologies Group PLC (AIM:LTG, OTC:LTTHF) chief executive Jonathan Satchell talked with Proactive's Stephen Gunnion about the company’s transition to private ownership following its acquisition by private equity group General Atlantic. Satchell reflected on LTG’s journey from its 2013 listing to its rapid growth, driven by acquisitions and strong investor backing. However, he noted that the last three years brought challenges, including market shifts and a declining share price, which

en

00:03:47

Cobalt Blue to rebrand and move into copper

Proactive - Interviews for investors ·

2025/02/18

Cobalt Blue Holdings Ltd (ASX:COB, OTC:CBBHF) investor relations representative Joel Crane talked with Proactive’s Tylah Tully about the company’s earn-in for the Halls Creek Project and its proposal to rebrand as Core Blue Minerals Ltd. Crane explains that Halls Creek is a significant polymetallic copper resource with notable zinc and silver grades. The project is located in a well-established mining jurisdiction and comes with existing mining leases, positioning the company ahead in the

en

00:02:11

Just the Facts: Riversgold secures 80% stake in...

Proactive - Interviews for investors ·

2025/02/18

Riversgold Ltd has exercised its option to acquire an 80% interest in the Kalgoorlie Gold Project’s Northern Zone in Western Australia after meeting the required A$600,000 minimum exploration expenditure. The company has formally notified Oracle Power Plc (LON: ORCP), the current owner, in accordance with ar Heads of Agreement signed in May 2023. Exploration efforts have identified a significant blind porphyry gold system, with widths of up to 600 metres and mineralisation extending beyond 400

en

00:02:10

Just the Facts: Ionic Rare Earths has major...

Proactive - Interviews for investors ·

2025/02/18

Ionic Rare Earths Ltd has reported a potential 30-50% reduction in the carbon footprint of its rare earth oxide (REO) production compared to conventional producers. A preliminary Life Cycle Assessment (LCA) conducted by Minviro on the magnet recycling process of subsidiary Ionic Technologies has highlighted significant environmental benefits. The results are undergoing peer review, with final findings expected in March 2025. Ionic Technologies’ Belfast commercial recycling plant will focus on

en

00:01:16

Just the Facts: Asian Battery Metals gears up for...

Proactive - Interviews for investors ·

2025/02/18

Asian Battery Metals PLC has identified priority drilling areas at the Oval Copper-Nickel Project in southwest Mongolia ahead of its Phase 3 exploration program, scheduled to begin next month. The program will include up to 1,500 metres of diamond drilling, downhole electromagnetic (DHEM) surveys and regional geophysical surveys. Drilling will focus on untested or modified DHEM conductive plates identified from the Phase 2 exploration work. Additionally, the company will investigate a high gravity

en

00:10:02

Recce Pharmaceuticals' R327G has 93% success in Phase...

Proactive - Interviews for investors ·

2025/02/18

Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) director & chief medical advisor Dr Alan Dunton and executive chairman Dr John Prendergast talked with Proactive’s Tylah Tully about the company’s latest Phase 2 clinical trial results for RECCE® 327, a topical gel targeting Diabetic Foot Infections (DFIs) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Dr Dunton explained that the Phase 2 study was conducted across three sites in Australia, testing the gel in 30 patients. The results

en

00:04:50

Tonix Pharmaceuticals reports positive phase 1...

Proactive - Interviews for investors ·

2025/02/17

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to discuss promising topline results from the company's Phase 1, single ascending dose trial of TNX-1500 in healthy participants. The trial evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500 and was designed to support dosing for an upcoming Phase 2 trial in kidney transplant recipients. Two published studies in the American Journal of Transplantation demonstrated that

en

00:05:02

Ondo InsurTech expands in US with PURE partnership

Proactive - Interviews for investors ·

2025/02/17

Ondo InsurTech PLC CEO Craig Foster talked with Proactive's Stephen Gunnion about the company’s continued expansion in the US, following the latest agreement with Privilege Underwriters Reciprocal Exchange (PURE). The high-net-worth insurer has expanded its use of Ondo’s LeakBot technology beyond its pilot in New York into six more states—Indiana, North Carolina, New Jersey, Ohio, Pennsylvania, and Washington. Foster explained that PURE initially wanted to test the company’s customer service

en

00:05:23

hVIVO expands hMPV research with £2M deal

Proactive - Interviews for investors ·

2025/02/17

hVIVO PLC chief executive Yamin ‘Mo’ Khan talked with Proactive's Stephen Gunnion about the company’s newly inked £2 million contract with a biotech client. The deal will fund the final stage of hVIVO’s human metapneumovirus (hMPV) characterisation study, paving the way for future human challenge trials. Khan explained that hVIVO had already completed a successful pilot study involving a small group of volunteers. The new study will expand the trial to a larger population to confirm infection

en

00:02:07

Just the facts: Battery-grade graphite achieved in...

Proactive - Interviews for investors ·

2025/02/17

International Graphite (ASX: IG6) has completed successful purification test-work on graphite from its Springdale Graphite Project in Western Australia. The test-work, coordinated by Japan’s Marubeni Corporation, achieved total graphitic carbon (TGC) purity of up to 99.97%, meeting lithium-ion battery anode specifications. The bench-scale program used graphite concentrates from drilling and bulk concentrate extraction conducted in 2023. Further purification test-work is planned. Marubeni, one of

en

00:02:08

Just the Facts: Recce Pharmaceuticals scores 93%...

Proactive - Interviews for investors ·

2025/02/17

Recce Pharmaceuticals Ltd has received positive Phase II clinical trial results for RECCE® 327 Topical Gel (R327G) in treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including Diabetic Foot Infections (DFI). The study achieved a 93% primary efficacy endpoint over 14 days, with an interim response rate of 86% at seven days. No serious adverse events were reported. These results support Recce’s upcoming Phase III registrational study for DFI in Indonesia, which has been

en

4,496 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...